Navigation Links
Tianyin Pharmaceutical Co., Inc. to Host Third Fiscal Quarter 2010 Results Earnings Conference Call on Wednesday, May 12, 2010 at 9:00 a.m. ET
Date:5/7/2010

CHENGDU, China, May 7 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE Amex: TPI), a biopharmaceutical company that develops, manufactures and sells modernized traditional Chinese medicine ("TCM") and branded generics based in Chengdu, China, today announced that the senior management will host a conference call to discuss its fiscal 2010 third quarter results at 9:00 a.m. ET on Wednesday, May 12, 2010.

Interested parties may access the call by dialing +1-877-941-4776 (U.S.), or +1-480-629-9762 (International). The conference ID is 4297414. It is advisable to dial in approximately 5-10 minutes prior to the start of the call.

A replay will be available through May 26, 2010 and can be accessed by dialing +1-800-406-7325 (U.S.), or +1-303-590-3030 (International), passcode 4297414.

This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://viavid.net/dce.aspx?sid=00007515

This event is optimized for Microsoft's Windows media player version 9. To download, please go to http://www.microsoft.com/windows/windowsmedia/download .

About Tianyin Pharmaceutical

Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, Sichuan Province of China, is a leading biopharmaceutical company that specializes in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and branded generics. Tianyin is equipped with two state-of-the-art manufacturing facilities and an extensive nationwide sales and distribution network throughout China. Tianyin currently manufactures and markets a comprehensive portfolio of 50 products, of which 23 are listed in the highly selective National Medicine Catalog of the National Medical Insurance program, 7 are included in the essential drug list of China. Tianyin achieved 10 new drug approvals at SFDA in 2009 and has a pipeline of 12 products pending regulatory approval that target various indications with considerable market potential. Tianyin has an extensive nationwide distribution network with a sales force of 720 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    Tianyin Pharmaceutical Co., Inc.
     James Jiayuan Tong  M.D. Ph.D.
     Chief Financial Officer, Chief Business & Development Officer
     Director
     Add:   23rd Floor Unionsun Yangkuo Plaza
            No. 2, Block 3, South Renmin Road
            Chengdu, 610041
            China
     Web:   http://www.tianyinpharma.com
     Email: Dr.Tong@tianyinpharma.com
     Tel:   +86-28-8551-6696 (Chengdu, China)
            +1-949-350-6999 (U.S.)


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
2. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
3. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
4. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
5. Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
6. Catalyst Pharmaceutical Partners to Present at the MoneyShow Conference
7. DUSA Pharmaceuticals Reports Notice of Allowance for Key PDT Device Patent
8. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
9. ADVENTRX Pharmaceuticals Announces Closing of Financing
10. Waters Corporation and NIBRT Partner to Bring Greater Control and Predictability to Biopharmaceutical Processing
11. DUSA Pharmaceuticals, Inc.(R) to Host First Quarter 2010 Corporate Highlights and Financial Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/14/2017)... It should come as no surprise to anyone ... the midst of a crippling opioid epidemic. According to the ... of overdose deaths from opiate-based medications has quadrupled, Says, Dr. ... dead from 2001 to 2015". During this time, the prescription ... quadrupled, drawing a compelling link between prescription and eventual addiction. ...
(Date:7/12/2017)... July 12, 2017  Eli Lilly and Company (NYSE: ... generic companies to resolve pending patent litigation in the U.S. ... regarding the Cialis ® (tadalafil) unit dose ... 26, 2020. As part of the agreement, Cialis exclusivity is ... 2018. "The unit dose patent for Cialis is ...
Breaking Medicine Technology:
(Date:7/28/2017)... ... ... The DuPage County law firm of Mirabella Kincaid Frederick & Mirabella, ... Cusack joins the team ready to provide clients with vigorous representation in a number ... Illinois, with a BA in Social Work. She earned her JD from Western Michigan ...
(Date:7/28/2017)... ... 2017 , ... Gocella Insurance Agency, a Cheektowaga based partnership ... in and around the greater Buffalo metropolitan area, is announcing the firm’s 25th ... The Make-A-Wish Foundation is an internationally recognized nonprofit that works to improve the ...
(Date:7/27/2017)... Denville, NJ (PRWEB) , ... July 27, 2017 ... ... now a Diplomate of the American Board of Oral Implantology/Implant Dentistry (ABOI/ID). After ... one of the nation’s leading providers of dental implants . Dr. Kimowitz ...
(Date:7/27/2017)... Viejo, CA (PRWEB) , ... July 27, 2017 , ... ... Cut Pro X . This Final Cut Pro X exclusive features transitions that contain ... and add rotation to the transition using intuitive drop-down menus. TransPanel Volume 4 makes ...
(Date:7/27/2017)... ... July 27, 2017 , ... ... announces the internal promotion of Elrene Clinkscales to Vice President of Revenue Cycle ... Remittance Management, reporting to Derek Morkel, chief executive officer (CEO). , Elrene has ...
Breaking Medicine News(10 mins):